135 related articles for article (PubMed ID: 8946474)
1. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population.
Agúndez JA; Olivera M; Martínez C; Ladero JM; Benítez J
Pharmacogenetics; 1996 Oct; 6(5):423-8. PubMed ID: 8946474
[TBL] [Abstract][Full Text] [Related]
2. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population.
Mrozikiewicz PM; Cascorbi I; Brockmöller J; Roots I
Clin Pharmacol Ther; 1996 Apr; 59(4):376-82. PubMed ID: 8612380
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.
Cascorbi I; Drakoulis N; Brockmöller J; Maurer A; Sperling K; Roots I
Am J Hum Genet; 1995 Sep; 57(3):581-92. PubMed ID: 7668286
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer and mutations at the polymorphic NAT2 gene locus.
Martínez C; Agúndez JA; Olivera M; Martín R; Ladero JM; Benítez J
Pharmacogenetics; 1995 Aug; 5(4):207-14. PubMed ID: 8528267
[TBL] [Abstract][Full Text] [Related]
5. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients.
Agúndez JA; Ladero JM; Olivera M; Abildúa R; Román JM; Benítez J
Oncology; 1995; 52(1):7-11. PubMed ID: 7800347
[TBL] [Abstract][Full Text] [Related]
7. Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population.
Aynacioglu AS; Cascorbi I; Mrozikiewicz PM; Roots I
Pharmacogenetics; 1997 Aug; 7(4):327-31. PubMed ID: 9295061
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population.
Agúndez JA; Martínez C; Olivera M; Ledesma MC; Ladero JM; Benítez J
Clin Pharmacol Ther; 1994 Aug; 56(2):202-9. PubMed ID: 8062497
[TBL] [Abstract][Full Text] [Related]
9. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification.
Doll MA; Fretland AJ; Deitz AC; Hein DW
Anal Biochem; 1995 Nov; 231(2):413-20. PubMed ID: 8594994
[TBL] [Abstract][Full Text] [Related]
10. Re-investigation of the concordance of human NAT2 phenotypes and genotypes.
Bolt HM; Selinski S; Dannappel D; Blaszkewicz M; Golka K
Arch Toxicol; 2005 Apr; 79(4):196-200. PubMed ID: 15558239
[TBL] [Abstract][Full Text] [Related]
11. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.
Kotila OA; Fawole OI; Olopade OI; Ayede AI; Falusi AG; Babalola CP
Pharmacogenet Genomics; 2019 Jul; 29(5):106-113. PubMed ID: 30882558
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
Wadelius M; Stjernberg E; Wiholm BE; Rane A
Pharmacogenetics; 2000 Feb; 10(1):35-41. PubMed ID: 10739170
[TBL] [Abstract][Full Text] [Related]
13. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.
Bakayev VV; Mohammadi F; Bahadori M; Sheikholslami M; Javeri A; Masjedi MR; Velayati AA
Eur J Clin Pharmacol; 2004 Sep; 60(7):467-71. PubMed ID: 15316701
[TBL] [Abstract][Full Text] [Related]
14. N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.
Djordjevic N; Carrillo JA; Ueda N; Gervasini G; Fukasawa T; Suda A; Jankovic S; Aklillu E
J Clin Pharmacol; 2011 Jul; 51(7):994-1003. PubMed ID: 20801937
[TBL] [Abstract][Full Text] [Related]
15. N-acetyltransferase 2 polymorphism and acetylation profiles in Buginese ethnics of Indonesia.
Yuliwulandari R; Susilowati RW; Razari I; Viyati K; Umniyati H; Prayuni K
Ann Hum Genet; 2019 Nov; 83(6):465-471. PubMed ID: 31332782
[TBL] [Abstract][Full Text] [Related]
16. Arylamine N-acetyltransferase-2 genotypes in the Thai population.
Kukongviriyapan V; Prawan A; Tassaneyakul W; Aiemsa-Ard J; Warasiha B
Br J Clin Pharmacol; 2003 Mar; 55(3):278-81. PubMed ID: 12630978
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus.
Agúndez JA; Menaya JG; Tejeda R; Lago F; Chávez M; Benítez J
Pharmacogenetics; 1996 Oct; 6(5):465-72. PubMed ID: 8946479
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
19. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients.
Schnakenberg E; Ehlers C; Feyerabend W; Werdin R; Hübotter R; Dreikorn K; Schloot W
Clin Genet; 1998 May; 53(5):396-402. PubMed ID: 9660060
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
